Arterra Bioscience SpA (MIL:ARBS) Debt-to-EBITDA : 0.22 (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Arterra Bioscience SpA Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Arterra Bioscience SpA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.04 Mil. Arterra Bioscience SpA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.30 Mil. Arterra Bioscience SpA's annualized EBITDA for the quarter that ended in Jun. 2024 was €1.59 Mil. Arterra Bioscience SpA's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 0.22.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Arterra Bioscience SpA's Debt-to-EBITDA or its related term are showing as below:

MIL:ARBS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.16 Med: 0.5 Max: 0.8
Current: 0.16

During the past 7 years, the highest Debt-to-EBITDA Ratio of Arterra Bioscience SpA was 0.80. The lowest was 0.16. And the median was 0.50.

MIL:ARBS's Debt-to-EBITDA is ranked better than
80.99% of 284 companies
in the Biotechnology industry
Industry Median: 1.54 vs MIL:ARBS: 0.16

Arterra Bioscience SpA Debt-to-EBITDA Historical Data

The historical data trend for Arterra Bioscience SpA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arterra Bioscience SpA Debt-to-EBITDA Chart

Arterra Bioscience SpA Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

0.80

0.50

0.35

0.21

Arterra Bioscience SpA Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-EBITDA	Get a 7-Day Free Trial									0.23	0.22	0.49	0.15	0.22

Competitive Comparison of Arterra Bioscience SpA's Debt-to-EBITDA

For the Biotechnology subindustry, Arterra Bioscience SpA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arterra Bioscience SpA's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Arterra Bioscience SpA's Debt-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Arterra Bioscience SpA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Arterra Bioscience SpA's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.086	+	0.3)	/	1.844
	=	0.21

Arterra Bioscience SpA's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.043	+	0.3)	/	1.586
	=	0.22

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.

Arterra Bioscience SpA (MIL:ARBS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Arterra Bioscience SpA Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Arterra Bioscience SpA's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Arterra Bioscience SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arterra Bioscience SpA (MIL:ARBS) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

via Benedetto Brin, 69, Napoli, ITA, 80142

Website

https://www.arterrabio.it

Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.

Arterra Bioscience SpA Headlines

No Headlines